Search the Newsreel

Corteva files amendment for Vylor seed business spin-off with SEC

Corteva, Inc. announced that its subsidiary, Vylor, Inc., has filed an amendment to its Form 10 registration statement with the SEC, detailing Vylor’s business operations, strategy, and historical financial results. This filing is a step towards spinning off Corteva's seed business into an independent, …

Form 8K Corteva Inc For: 14 August By Investing.com

This article announces that Corteva Inc. filed a Form 8K on August 14. It briefly mentions the company's stock symbol CTVA and its stock performance. The article is a concise notification about the filing.

Corteva Inc. stock outperforms competitors on strong trading day

Corteva Inc. (CTVA) shares rose by 1.17% to $76.68 on Friday, despite a generally negative trading day for the broader market, with both the S&P 500 and Dow Jones Industrial Average experiencing declines. This marked the second consecutive day of gains for Corteva's stock, …

Artisan Partners (STVN) discloses 2.6M Stevanato shares held for clients

Artisan Partners entities have reported a beneficial ownership of 2,601,598 ordinary shares in Stevanato Group S.p.A. This stake represents 5.2% of the class, based on 49,709,718 shares outstanding as of March 31, 2026. The shares are held on behalf of discretionary clients of Artisan …

Teva snaps six-session rally, closes flat in the red (TEVA:NYSE)

Teva Pharmaceutical Industries Limited (TEVA) ended a six-session winning streak, closing down 0.6% at $36.52. The stock briefly slipped into negative territory before market close, despite being on track for further gains. Analysts attribute Teva's recent outperformance to its 'Pivot to Growth' strategy and …

Teva Pharmaceutical Industries (NYSE:TEVA) Sets New 1-Year High After Analyst Upgrade

Stevanato Group S.p.A. (STVN) Stock Forecasts

Morningstar has initiated coverage on Stevanato Group S.p.A. (STVN) with a narrow moat rating and a fair value estimate of USD 21.10. The shares are currently considered fairly valued at their current price of 21.52. Stevanato Group provides glass and polymer drug containment, drug …

Teva stock hits 52-week high at 37.35 USD

Teva Pharmaceutical Industries Ltd ADR has reached a 52-week high of $37.38, marking a 113% increase in its stock price over the past year and bringing its market capitalization to $43.07 billion. This surge reflects investor confidence, supported by analysts revising earnings upwards and …

Judge in Inari-Corteva Suit Wants Answers About Sponsored Ad

A Delaware judge has ordered agricultural company Inari to explain how a sponsored online advertisement, which appeared ahead of a patent trial against Corteva Agriscience LLC, complies with professional conduct rules. The judge is questioning whether the ad, titled "The Facts on Seed Litigation," …

Corteva (NYSE:CTVA) Stock Rating Lowered by Zacks Research

Zacks Research downgraded Corteva (NYSE:CTVA) from a "strong-buy" to a "hold" rating, though the overall analyst consensus remains a "Moderate Buy" with a $91.70 target price. Despite exceeding EPS expectations with $2.30 against a forecast of $2.24, Corteva's revenue of $6.38 billion missed estimates …

Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $42

Barclays has reiterated its Buy rating on Teva Pharmaceutical Industries (TEVA.US) and increased its price target from $38 to $42. This revised target suggests a potential upside of 11.23% from the stock's last closing price of $37.76.

Capital World Investors (NYSE: CTVA) reports 6.6% ownership stake in Corteva

Capital World Investors has reported a 6.6% ownership stake in Corteva, Inc., totaling 43,841,218 shares of common stock. This beneficial ownership includes sole voting power over 43,417,923 shares and sole dispositive power over all 43,841,218 shares. The filing indicates this stake is held across …

Corteva's Higher 2026 Guidance Puts Investor Focus on Growth Drivers

Corteva, Inc. CTVA delivered a mixed second-quarter 2026 performance, with earnings exceeding expectations while revenues fell short of the Zacks Consensus Estimate. The company raised its full-year outlook, supported by Seed technology demand, productivity initiatives and new Crop Protection products. However, investors must weigh …

Corteva Growth Improves, But Valuation Limits Upside

Corteva, Inc. CTVA is showing improving earnings momentum as technology adoption, productivity actions and a stronger Seed business support growth. However, the stock's valuation and ongoing Crop Protection pricing pressures keep the risk-reward balance more measured. The stock currently carries a Zacks Rank #3 …

Corteva, Inc. $CTVA Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB significantly reduced its stake in Corteva, Inc. by 13.3% in the second quarter, selling 53,264 shares and now owning 347,071 shares valued at $29.39 million. Despite this, other institutional investors have recently acquired new stakes or increased their holdings in Corteva. …

Pacer Advisors Inc. Sells 484,736 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Teva (TEVA) legt um 6,0 % zu, nachdem Moody’s das Rating auf „Investment Grade“ angehoben und die Prognose für 2026 nach oben korrigiert hat

Stevanato Group S.p.A. (NYSE:STVN) Receives Consensus Recommendation of "Buy" from Brokerages

Stevanato Group S.p.A. (NYSE:STVN) has received a consensus "Buy" recommendation from six analysts, with two holding, two buying, and two strong buying. Recent analyst coverage includes an "outperform" rating from Wolfe Research with a $21 price target and an upgrade to "strong-buy" from TD …

Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy

Moody’s Ratings has upgraded Teva Pharmaceutical Industries Ltd.'s corporate credit rating to Baa3 from Ba1, achieving investment-grade status with a stable outlook. This upgrade reflects the success of Teva's "Pivot to Growth" strategy, driven by key innovative products, an expanded pipeline, and consistent debt …

Teva (TEVA) Is Up 6.0% After Moody’s Upgrade To Investment Grade And Higher 2026 Guidance

Teva Pharmaceutical Industries (TEVA) stock rose 6.0% following a Moody's upgrade to investment-grade Baa3 with a stable outlook, and increased 2026 revenue guidance to US$16.5 billion - US$16.85 billion. This upgrade reflects Teva's shift towards innovative medicines and debt reduction efforts, despite a Q2 …

Corteva Seed-Patent Suit Gets Trimmed Ahead of September Trial

A federal judge has limited the scope of an upcoming patent trial between Corteva Inc. and Inari Agriculture Inc., ruling that Inari cannot claim false advertising against Corteva. Inari had alleged false advertising based on a Corteva press release, but the court found no …

Chief Financial Officer At Stevanato Group Sells $84K Of Stock

Marco Lago Dal, the Chief Financial Officer at Stevanato Group (NYSE: STVN), recently sold 4,209 shares of the company's stock for a total transaction value of $84,558. This insider sell, reported in an SEC Form 4 filing, comes as Stevanato Group's shares were up …

Teva Pharmaceutical Industries Ltd. Receives Moody’s Upgrade to Investment-Grade Baa3 Rating

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Rating of "Moderate Buy" by Brokerages

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has received a "Moderate Buy" consensus rating from ten research firms, with an average 12-month price target of $42.00. Several brokerages recently raised their price targets for Teva. The company's shares opened at $36.04, near their 52-week high, and …

Assenagon Asset Management S.A. Cuts Stock Position in Corteva, Inc. $CTVA

Assenagon Asset Management S.A. significantly reduced its stake in Corteva, Inc. by 65% in the second quarter, selling 324,734 shares and retaining 174,783 shares valued at approximately $14.8 million. Despite mixed financial results with EPS beating estimates but revenue falling short, Corteva maintained its …

Corteva Inc (CTVA) Stock News Today

This article provides recent news and analysis for Corteva Inc (CTVA) stock. It highlights a 10.51% stock price movement down on July 31st and includes links to other relevant stock news, such as Linde PLC. The page also provides current stock data for Corteva, …

Stevanato Group (STVN) Could Be 16% Undervalued Following Earnings And Guidance Update

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. What Stevanato Group's latest earnings and guidance mean for investors Stevanato Group (STVN) has …

TEVA PHARMACEUTICAL INDUSTRIES AKTIE: AI-Analysen, Prognose & Kursziel

Are Wall Street Analysts Bullish on Corteva Stock?

Corteva office in Wilmington By JHVEPhoto With a market cap of $51.3 billion, Corteva, Inc. (CTVA) is a global pure-play agriculture company providing innovative seed, crop protection, and digital solutions to address the world's most pressing agricultural challenges. Through its strong brands, advanced technology …

How Investors Are Reacting To Stevanato Group (STVN) Trimmed Guidance And New GLP-1 Pen Approvals

Stevanato Group S.p.A. recently reported past second-quarter 2026 results showing sales of €302 million with lower net income, slightly trimmed its full-year revenue guidance to €1.26–€1.28 billion, and outlined expected diluted EPS of €0.53–€0.55. At the same time, the company's Alina pen injector platform …

Stevanato Group (STVN) Stock Looks Cheap On Cash Flow But Pricey On Earnings

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Stevanato Group stock has declined 34.6% over the past three years, and current checks send mixed valuation signals, with an intrinsic value estimate …

Stevanato Group S.p.A. (STVN): Investor Outlook Reveals 23.83% Potential Upside

Stevanato Group S.p.A. (STVN), a healthcare company specializing in medical instruments, is currently trading at $20.27 with a market capitalization of $5.53 billion. Analysts predict a potential upside of 23.83%, with an average target price of $25.10. Despite negative free cash flow, the company …

TEVA (TEVA) director Tal Zvi Zaks sells 17 shares, retains 73,247

Tal Zvi Zaks, a director at TEVA PHARMACEUTICAL INDUSTRIES LTD, sold 17 Ordinary Shares at $34.8655 per share on August 5, 2026, in an open market or private transaction. Following this sale, Zaks directly holds 73,247 Ordinary Shares. The transaction was not executed under …